Mavyret Tablet, Film Coated
NDC Package 0074-2625-01
Package Information
Mavyret (glecaprevir and pibrentasvir) tablets is mAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). This formulation utilizes a tablet, film coated delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-2625 and is authorized under FDA application NDA209394.
Identification & Billing
- RxCUI: 1940703 - glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet
- RxCUI: 1940709 - Mavyret 100 MG / 40 MG Oral Tablet
- RxCUI: 1940709 - glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet [Mavyret]
- RxCUI: 1940709 - Mavyret (glecaprevir 100 MG / pibrentasvir 40 MG) Oral Tablet
- RxCUI: 2557906 - glecaprevir 50 MG / pibrentasvir 20 MG per packet Oral Pellet
Clinical Specifications
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 1A2 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- HCV NS3/4A Protease Inhibitors - [MoA] (Mechanism of Action)
- Hepatitis C Virus NS3/4A Protease Inhibitor - [EPC] (Established Pharmacologic Class)
- Hepatitis C Virus NS5A Inhibitor - [EPC] (Established Pharmacologic Class)
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporting Polypeptide 1B3 Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
- UGT1A1 Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 0074 - Abbvie Inc.
- 0074-2625 - Mavyret
- 0074-2625-01 - 1 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PACK
- 0074-2625 - Mavyret
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0074-2625). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0074-2625-01 identifies a specific commercial package of 1 dose pack in 1 carton / 3 tablet, film coated in 1 dose pack of Mavyret, a human prescription drug labeled by Abbvie Inc.. This tablet, film coated is formulated for oral use and contains pibrentasvir; glecaprevir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on August 03, 2017. The current certification is valid through December 31, 2027.
How is this Abbvie Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074262501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.